Pharmaceutical

China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer

China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).

Aug 27, 2024 - 04:00
China NMPA grants approval for GenFleet’s fulzerasib to treat lung cancer
China has granted approval for GenFleet Therapeutics’ fulzerasib for advanced non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

Invenra’s antibody gains US FDA designations for neuroblastoma treatment

Next Article

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Accolade beats analyst estimates, Teladoc’s optimism, and more JPM health tech news

Accolade beats analyst estimates, Teladoc’s optimism, a...

Jan 12, 2024

Opinion: The Supreme Court’s affirmative action decision puts lives at risk

Opinion: The Supreme Court’s affirmative action decisio...

Jun 30, 2023

STAT+: Congress’ negotiations over doc pay, health centers fell apart ahead of spending extension

STAT+: Congress’ negotiations over doc pay, health cent...

Jan 18, 2024